Thrombocytopenia is a common adverse reaction during celinoxetine treatment. Whether or not to discontinue the medication depends primarily on its severity and the patient's overall condition. Patients should adjust their medication regimen under the guidance of their physician and should not self-medicate to avoid adverse reactions affecting their condition.
Monitor platelet counts at baseline and throughout celinoxetine treatment. Monitor more frequently during the first three months of treatment. Administer platelet transfusions and/or other treatments as clinically indicated. Monitor for signs and symptoms of bleeding and assess them promptly. Discontinue, reduce the dose, or permanently discontinue the medication under the guidance of a physician, depending on the severity of the adverse reaction.
Dosage Adjustment for Thrombocytopenia with Celinixol Treatment
1. When the platelet count is 25,000 to below 75,000/mcL, the celinixol dose is reduced by one dose level. Specifically, when used in combination with bortezomib and dexamethasone, the celinixol dose is 80 mg once weekly.
2. If the platelet count is 25,000 to below 75,000/mcL with concurrent bleeding, discontinue celinixol. Restart celinixol at a lower dose level (40 mg once weekly). After bleeding subsides, administer platelet transfusions according to clinical guidelines.
3. If the platelet count is below 25,000/mcL, discontinue celinixol. Monitor until the platelet count recovers to at least 50,000/mcL. Restart celinixol at a lower dose level (40 mg once weekly).
Symptoms of Celinixol Thrombocytopenia
Celinixol can cause life-threatening thrombocytopenia, potentially leading to bleeding.
In multiple myeloma patients receiving celinixol 100 mg once weekly, 92% reported thrombocytopenia, and 43% reported severe (grade 3-4) thrombocytopenia. The median time to first onset for any grade of thrombocytopenia was 22 days, and for grade 3 or 4, it was 43 days. Bleeding occurred in 16% of patients with thrombocytopenia, with 4% experiencing clinically significant bleeding (grade 3 bleeding) and 2% experiencing fatal bleeding. 2% of patients permanently discontinued celinixol due to thrombocytopenia.
In multiple myeloma patients receiving celinixol 80 mg twice weekly, 74% reported thrombocytopenia as an adverse reaction, and 61% reported severe (grade 3-4) thrombocytopenia. The median time to first event was 22 days. Bleeding occurred in 23% of patients with thrombocytopenia, with clinically significant bleeding in 5% and fatal bleeding in less than 1%.
In DLBCL patients treated twice weekly with celinixol 60 mg, 86% experienced thrombocytopenia or worsening, with 49% experiencing grade 3-4 thrombocytopenia (grade 4, 18%). The median time to first event was 28 days for any grade of thrombocytopenia and 33 days for grade 3 or 4 thrombocytopenia.
Celinixol Usage Instructions
1. If you are allergic to celinixol, any other medication, or any component of celinixol tablets, inform your doctor immediately.
2. If you have or have recently had an infection, if you have or have had bleeding problems, or if you have cataracts, inform your doctor immediately.
3. If you are pregnant or planning to become pregnant, tell your doctor. You will need to take a negative pregnancy test before starting celinox.
4. You should not breastfeed while taking celinox and for one week after your last dose.
5. If you experience any side effects, your doctor may need to stop or interrupt your treatment or reduce the dose. Be sure to tell your doctor how you feel while using celinox.
